Affitech

Oslo Research Park, Gaustadalléen 21, N-0349 Oslo NORWAY 1945 Arbol Grande, Walnut Creek, CA

Affitech has developed technologies for the generation and use of human antibodies. The Company’s proprietary technologies includes its worldwide patent position on phagemid-display of antibodies. The antibodies selected from Affitech's libraries are of human origin, thus they are perfect reagents for in vivo administration. Affitech has a variety of vectors for the expression of the selected antibodies as scFv or Fab in bacteria or for the regeneration of intact fully human antibodies by any isotype of choice for the expression in eukaryotic cells.

Affymax

4001 Miranda Avenue, Palo Alto, CA 94304

Affymax is leading the way in creating novel approaches for improving patient care for serious and life-threatening conditions in kidney disease and cancer. We are building a pipeline of peptide drugs against clinically validated targets that demonstrate significant advantages over currently marketed protein products. Our flagship drug candidate, Hematide™, is a next-generation erythropoiesis stimulating agent (ESA) that has been designed to stimulate the production of red blood cells for the treatment of anemia caused by chronic disease.

Affymetrix Inc
(AFFX) 4.50

3380 Central Expressway, Santa Clara, CA 95051

Affymetrix, Inc. is engaged in the field of DNA chip technology. Affymetrix has developed and intends to establish its GeneChip system and related microarray technologies as platforms for acquiring, analyzing and managing genetic information. The GeneChip system consists of disposable DNA probe arrays containing gene sequences on a chip, certain reagents for use with the probe arrays, a scanner and other instruments to process the probe arrays and software to analyze and manage genetic information from the probe arrays. Related microarray technology offered includes instrumentation, software and licenses for fabricating, scanning, collecting and analyzing results from low-density microarrays. The Company sells its products directly to pharmaceutical and biotechnology companies, academic research centers, private foundations and clinical reference laboratories in the United States and Europe. The Company also sells its products through certain distributors, principally in Japan.

Alpha Innotech
*VENDOR*

2401 Merced St., San Leandro, CA 94577

Alpha Innotech is a genomic tools company providing signal detection, digital imaging and application support to the Life Science markets since 1992. Our new modular technology platforms combine instruments, reagents and bioinformatics to offer integrated solutions for functional genomics and gene expression analysis.

Amyris Biotechnologies, Inc.

5980 Horton Street, Ste. 350, Emeryville, CA 94608

Amyris uses engineered microbes and rapid enzymatic pathway construction techniques to build microorganisms capable of producing high-value compounds, from renewable biofuels to pharmaceuticals. Amyris is using synthetic biology techniques to build biological solutions to important global problems. We focus on creating new metabolic pathways in microbes, essentially re-programming them to function as living factories for the environmentally-friendly production of high-value chemicals. Our first project converts a microbe known for its ability to make copious amounts of alcohol, such as yeast, into a chemical factory for a proven anti-malarial drug. Our second project is the development of a fermentation process that uses custom-designed microbes to renewably produce second-generation, high-performance biofuels that are cost-effective and compatible with current automotive and distribution technologies.

Anacor Pharmaceuticals

1060 East Meadow Circle, Palo Alto, CA 94303-4230

Anacor is committed to the discovery and development of novel antiinfectives for the treatment of serious bacterial and fungal infections. We are an early stage company founded to develop technology that was created at Stanford University and The Pennsylvania State University.

Anesiva Inc.
(ANSV) 0.00

1651 Page Mill Rd, Palo Alto, CA 94304

Anesiva is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. We have two product candidates in various stages of development.

Arriva Pharmaceuticals, Inc.

2020 Challenger Dr, Alameda, CA 94501

Arriva Pharmaceuticals, Inc. is focused on the development and commercialization of anti-inflammatory therapies for the treatment of respiratory diseases. Arriva's current clinical focus is the development of recombinant alpha 1-antitrypsin (rAAT) for hereditary emphysema.

ARYx Therapeutics
(ARYX) 0.39

6300 Dumbarton Circle, Fremont, CA 94555

ARYx discovers and develops novel drugs for large, chronic disease markets, unresolved by currently available therapies due to limitations in drug design and metabolism problems, including gastrointestinal disorders, atrial fibrillation and anticoagulation.

Aspira Biosystems, Inc.

849 Mitten Road, Suite 101, Burlingame, CA 94010

Aspira Biosystems is developing technology that enables the capture, with very high specificity, of targeted proteins. Aspira is actively seeking academic and commercial partners to develop therapeutic, medical research and industrial applications based on Partial Molecular Imprinting (PMI), our patented protein capture platform. Advanced Artificial Antibody Technology. Aspira is a wholly owned subsidiary of Nanomune Technologies, Inc. Nanomune's main shareholders are Archangel BioVentures, LLC and Alloy Ventures, Inc.

Avigen Inc
(AVGN) 0.00

1301 Harbor Bay Parkway, Suite 1000, Alameda, CA 94502

Avigen is a leader in the development of gene therapy products to treat serious, chronic diseases. Our gene therapy products are designed for in vivo administration to achieve the production of therapeutic proteins within the body. We are developing a new broad-based proprietary gene delivery technology - AAV (adeno-associated virus vectors) for use in the clinic.

Biomarin Pharmaceuticals
(BMRN) 22.62

371 Bel Marin Keys Blvd., Suite 210, Novato, CA 94949

BioMarin develops enzyme therapies for serious, life-threatening diseases and conditions.

BioSeek, Inc.

863-C Mitten Rd, Burlingame, CA 94010

BioSeek is committed to improving the success rate of pharmaceutical development by integrating human biology from the early stages of drug discovery through preclinical development. Our BioMAP® systems incorporate predictive human cell-based disease models that generate uniquely informative biological activity signatures for each potential drug, yielding actionable data to drive the selection and development of new drug candidates. We are leveraging our BioMAP technology in collaborations to enhance the productivity of our pharmaceutical partners’ pipelines, and in our internal programs to identify promising compounds for proprietary development in the fields of inflammation, cardiovascular disease and related indications. Our vision is to harness the predictive power of integrative cell systems biology to improve human health.

BioTime Inc
(BTIM.OB) 0.00

6121 Hollis Street Emeryville, CA 94608

BioTime, Inc.is developing synthetic solutionsfor use as blood plasma volume expanders, blood substitutes during hypothermic surgery and organ preservation solutions. The products of the company includes Hextend(R), PentaLyte(R) and HetaCoolTM. The products are used in emergency treatment of blood loss due to traumatic injury, cardio-pulmonary bypass surgery, the preservation of body organs and tissues awaiting transplant, cancer treatment and other biomedical applications. The customers of the company include anesthesiologists, surgeons and hospital pharmacists.

Caliper Life Sciences
(CALP) 3.47

68 Elm St., Hoplinton, MA 01748 605 Fairchild Dr, Mountain View, CA 94043

Caliper Life Sciences provides leading microfluidic, liquid handling, and integrated laboratory automation solutions to the worldwide life science industry. Through its expertise in microfluidics, Caliper is uniquely positioned to lead the industry by evolving the company's liquid handling, detection, and integration platforms into technologically advanced LabChip systems that offer the efficiency, versatility, and exquisite data that key scientists in the pharmaceutical industry already rely on to drive their drug discovery programs.

Celera - An Applera Corp Business
(CRA) 7.05

1401 Harbor Bay Parkway, Alameda CA 94502-7099 45 West Gude Drive, Rockville, MD 20850

Celera has a successful molecular diagnostics business and powerful genomic and proteomic discovery platforms that have identified and validated new drug targets and biomarkers that will advance the practice of Targeted Medicine.

Cell Genesys Inc
(CEGE) 0.36

500 Forbes Boulevard, South San Francisco, CA 94404

The principal activity of the Group consists of the development and commercialization of gene therapies to treat major, life-threatening diseases, including cancer and AIDS.The company's programs currently use engineered genes and vectors ex vivo to impart new capabilities to certain of the patients imune cells, such as T cells and steam cells. the company's product development programs include cancer gene therapy and aids gene therapy.

CellSpecific

851 W. Midway Avenue, Suite 114, Alameda, CA 94501

CellSpecific (A Division of InTouch BioSolutions LLC) aims to provide the best in cell-based assay services, immune or non-immune cell assays, cell separation services, cell isolation services, cell purification services and cell differentiation services. We combine gold-standard methods and many years of experience to help advance understanding of drug effect and activity in a variety of purified cell systems.

Cepheid
(CPHD) 17.38

904 Caribbean Dr, Sunnyvale, CA 94089 81470 Maurens-Scopont FRANCE

Cepheid develops, manufactures, and markets fully-integrated systems that perform genetic analysis, including DNA and RNA analysis, for the clinical genetic assessment, biothreat, and life sciences markets. Our systems enable rapid, sophisticated genetic testing of organisms by automating otherwise complex manual laboratory procedures.

Cerus Corporation
(CERS) 3.67

2411 Stanwell Dr. SUITE 300, Concord, CA 94520

The principal activity of the Company is the development of systems designed to improve the safety of transfusion of blood products through inactivation of viruses, bacteria and other pathogens.The Company designs systems to treat platelets, fresh frozen plasma and red blood cells intended for transfusion, and to treat source plasma used for fractionation.During the year 2000, licenses, milestones and development funding accounted for 88% of revenues and revenues and Government grants, 12%.

ChemoCentryx

850 Maude Avenue, Mountain View, CA 94043

ChemoCentryx is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics for autoimmune diseases, inflammatory disorders and cancer.

Chiron Corporation

4560 Horton Street, Emeryville, CA 94608-2916

Chiron is the world leader in Nucleic Acid Testing for blood screening. Our PROCLEIX® products are used to test more than 25 million blood donations annually in countries around the world, preventing thousands of HIV-1, hepatitis and West Nile virus transfusion-transmitted infections.

Codexis, Inc.

200 Penobscot Drive, Redwood City, CA 94063

Codexis evolves enzymes for use in improving chemical manufacturing processes. Compared with chemical processing methods, enzyme-based methods are often faster, cleaner, and more efficient. The difficulty is that it is not always possible to find enzymes in nature that are suited to catalyzing a specific chemical reaction. Codexis’ technology makes it possible to customize enzymes capable of selectively and efficiently performing a desired chemical process. This technology, referred to as DNA shuffling, is part of a directed evolution program to manipulate the DNA blueprint of an enzyme. Starting with a diverse set of genes that encode for variations of the enzyme catalyst, Codexis recombines, or shuffles these DNA sequences to create new variants. Using sophisticated high-throughput screening methods, novel biocatalysts with desired improvements are selected and these improved variants can then be put through the process again until a highly efficient biocatalyst is created that meets or exceeds targeted performance characteristics.

Compugen Ltd
(CGEN) 4.19

560 S. Winchester Blvd., Suite 500, San Jose, CA 95128 72 Pinchas Rosen St. Tel Aviv, Israel 69512

Compugen's mission is to be the world leader in the discovery and licensing of product candidates to the drug and diagnostic industry. The Company's powerful discovery engines enable the predictive discovery of numerous potential therapeutics and diagnostic biomarkers. This capability results from the Company's decade-long pioneering efforts in the deeper understanding of important biological phenomena at the molecular level through the incorporation of ideas and methods from mathematics, computer science and physics into biology, chemistry and medicine.

Corcept Therapeutics
(CORT) 3.06

149 Commonwealth Drive, Menlo Park, CA 94025

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. Our lead product, CORLUX, is currently in three Phase 3 clinical trials for the treatment of the psychotic features of psychotic major depression (PMD), a disorder that affects approximately three million adults in the United States each year and for which there are no FDA - approved treatments. The drug is administered orally to PMD patients once per day for seven days. CORLUX, a potent GR-II antagonist, appears to mitigate the effects of the elevated and abnormal release patterns of cortisol seen in PMD. In August 2006 we announced negative top line results of one of our three Phase 3 studies. We expect to report the results the second study in September and the third in late 2006 or early 2007. Our program has been granted "fast track" status by the FDA. We have also initiated a proof-of-concept study evaluating the ability of CORLUX to mitigate weight gain associated with the use of olanzapine.

CV Therapeutics Inc
(CVTX) 0.00

3172 Porter Dr, Palo Alto, CA 94304

CV Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of new small molecule drugs for the treatment of cardiovascular diseases. We apply advances in molecular biology and genetics to identify mechanisms of cardiovascular diseases and targets for drug discovery.

Cytokinetics

280 East Grand Avenue, South San Francisco, CA 94080

Cytokinetics is a leading biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that may address areas of significant unmet clinical needs. Our development efforts are directed to advancing the movement of multiple drug candidates through clinical trials to demonstrate proof-of-concept in humans, specifically in the areas of heart failure and cancer.

diaDexus

343 Oyster Point Boulevard, South San Francisco, CA 94080

diaDexus is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus' lead product, the PLAC® test, is a blood test that measures the concentration of lipoprotein-associated phospholipase A2 (Lp-PLA2), a novel risk factor for cardiovascular disease. The PLAC test is the only blood test cleared by the FDA as an aid in determining risk for coronary heart disease, and ischemic stroke associated with atherosclerosis. Numerous published or presented studies, involving more than 20,000 subjects, highlight Lp-PLA2 as an important risk factor for cardiovascular disease.

DiscoveRx
*VENDOR/SERVICE*

42501 Albrae Street, Fremont, CA 94538

DiscoveRx® develops, manufactures, and commercializes reagents and complete assay kits for the drug discovery and screening markets. Our products, biochemical and cell-based assays, enable customers to improve research productivity and effectiveness, thus accelerating the discovery and development of new drugs.

Dynavax Technologies
(DVAX) 1.70

2929 Seventh Street, Suite 100, Berkeley, CA 94710 Eichsfelder Str. 11, 40595 Düsseldorf, Germany

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative therapeutic products to treat and prevent infectious diseases, allergies, and cancer. Our versatile, proprietary approaches alter specific immune responses by activating a unique receptor called Toll-Like Receptor 9 (TLR9) found on certain immune system cells. To target TLR9, we are using immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.

Entelos

4040 Campbell Avenue, Suite 200, Menlo Park CALIFORNIA 94025

Entelos is the leader in predictive biosimulation. Using its patented PhysioLab technology, Entelos develops dynamic large-scale computer models of human disease. Each PhysioLab platform provides a framework for integrating data (e.g., genomic, proteomic, physiologic, environmental) in the context of a disease or therapeutic area, focusing on understanding and determining clinical responses to potential treatment. Virtual patients are created within this framework to represent real patient subpopulations. Entelos builds and customizes its PhysioLab systems using thousands of peer-reviewed papers, the expertise of its in-house research teams and world-class scientific advisors, and the proprietary information of its collaboration partners.

Exelixis Inc
(EXEL) 3.85

210 East Grand Avenue, So. San Francisco, CA 94080

Exelixis is a genomics-based drug discovery company focused on the discovery and development of potential new drug therapies, specifically for cancer and other proliferative diseases. Our primary mission is to develop proprietary human therapeutics by leveraging our integrated gene-to-drug platform to increase the speed, efficiency and quality of pharmaceutical product discovery and development.

Five Prime Therapeutics

1650 Owens Street, Suite 200, San Francisco, CA 94158-2216

FivePrime Therapeutics, Inc. is a pre-clinical stage biotech company discovering and developing innovative protein and antibody therapeutics. FivePrime is using its world-class discovery platform to build a strong pipeline that currently includes products in development for cancer and diabetes and multiple leads in metabolic and immunologic diseases, oncology and regenerative medicine.

GeneData AG
*SERVICE*

Maulbeerstrasse 46 CH-4016 Basel SWITZERLAND Lena-Christ-Str. 50 D-82152 Martinsried GERMANY Suite 194 1601 Trapelo Road, Waltham, MA 02451 601 Gateway Blvd, Suite 610, South San Francisco, CA 94080-7001

Genedata provides sophisticated computational solutions for life science research using a combination of software systems and professional services developed in close collaboration with its customers and partners.

Genelabs Technologies Inc
(GNLB) 1.27

505 Penobscot Drive, Redwood City, CA 94063-4738

Genelabs Technologies, Inc. is a biopharmaceutical company focused on the discovery and development of pharmaceutical products to improve human health. We have built drug discovery capabilities that can support various research and development projects. Genelabs is currently concentrating these capabilities on discovering novel compounds that selectively inhibit replication of the hepatitis C virus and advancing preclinical development of compounds from this hepatitis C virus drug discovery program, while also developing a late-stage product for lupus.

Genencor Intl Inc

200 Meridian Centre Blvd., Rochester, NY 14618-3916 925 Page Mill Road, Palo Alto, CA 94304

The company produces protein (enzyme) products used for industrial applications in diverse consumer and industrial markets, ranging from grain processing to cleaning and textiles to biofuels and biosafety.

Genentech Inc
(DNA) 80.43

1 DNA Way, South San Fransisco CALIFORNIA 94080-4990

Considered the founder of the biotechnology industry, Genentech has been delivering on the promise of biotechnology for more than 30 years, using human genetic information to discover, develop, commercialize and manufacture biotherapeutics that address significant unmet medical needs. Today, Genentech is among the world's leading biotech companies, with multiple products on the market for serious or life-threatening medical conditions and over 50 projects in the pipeline. The company is the leading provider of anti-tumor therapeutics in the United States.

Genitope Corp.
(GTOP.PK) 0.02

6900 Dumbarton Cr, Fremont, CA 94555-3651

Genitope Corporation is a biotechnology company focused on the research and development of novel immunotherapies for the treatment of cancer. Immunotherapy products are designed to utilize the immune system to combat diseases such as cancer. Our lead product candidate, MyVax® Personalized Immunotherapy (previously referred to as GTOP-99) is currently in a pivotal Phase 3 trial for the treatment of follicular non-Hodgkin's lymphoma (f-NHL).

Geron Corporation
(GERN) 5.12

230 Constitution Drive, Menlo Park, CA 94025

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell-based therapeutics, with its spinal cord injury treatment anticipated to be the first product to enter clinical development.

Gilead Sciences, Inc
(GILD) 33.97

333 Lakeside Drive, Foster City, CA 94404 4 University Place 4611 University Drive Durham, NC 27707 650 Cliffside Drive, San Dimas, CA 91773 2025 1st Avenue, Suite 800, Seattle, WA 98121 7575 W. 103rd Avenue, Suite 102, Westminster, CO 80021

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide.

Guava Technologies
*VENDOR*

25801 Industrial Boulevard, Hayward, CA 94545-2991

Guava® Technologies is changing the way cell culture monitoring and cell screening assays are performed. Guava provides integrated solutions for the most important assays in cell-based analysis, making them accessible to everyone in the lab.

HTD Biosystems Inc.
*SERVICE*

551C Linus Pauling Drive, Hercules CALIFORNIA 94547

HTD Biosystems is a high throughput development contract laboratory, specialized in formulation of proteins, peptides and vaccines, using design of experiments (DoE).

Iconix Biosciences, Inc.

325 East Middlefield Road Mountain View, CA 94043

Iconix Biosciences, Inc. is pioneering the field of toxicogenomics, the integration of chemistry and genomics to profile drug candidates. Iconix’s toxicogenomic capabilities enable pharmaceutical companies to increase the odds of advancing the right compounds to the clinic, reducing attrition rates and the costs of drug discovery.

IMPAX Laboratories

30831 Huntwood Avenue, Hayward CA 94544 3735 Castor Avenue, Philadelphia, PA 19124

The mission for IMPAX Laboratories is to become a leader in the development, manufacturing and marketing of specialty prescription pharmaceutical products utilizing our formulation expertise and unique drug delivery technologies.

Institute for OneWorld Health

580 California St, Suite 900, San Francisco, CA 94104

Institute for OneWorld Health is a non-profit pharmaceutical company. The company is focused on developing cures for visceral leishmaniasis, diarrheal disease, malaria and Chagas disease. The company has been partially support by the Bill and Melissa Gates Foundation.

Intermune Inc
(ITMN) 11.52

3280 Bayshore Blvd., Brisbane, CA 94005

InterMune, Inc., is a biopharmaceutical company focused on developing and commercializing innovative therapies in hepatology and pulmonology. We market Actimmune® (interferon gamma-1b), approved for the treatment of severe, malignant osteopetrosis and chronic granulomatous disease. We have a late-stage and preclinical development pipeline in the areas of pulmonology and hepatology. In pulmonology, we are developing two therapies for the treatment of idiopathic pulmonary fibrosis (IPF): interferon gamma-1b and pirfenidone. In hepatology, we are focused on expanding treatment options for patients suffering from HCV infections. We have identified and characterized several highly potent preclinical HCV protease inhibitor candidates and are rapidly progressing one of them through toxicology and other IND-enabling activities. In addition, we are pursuing research related to other small molecules for unspecified hepatology targets.

Kosan Biosciences Inc
(KOSN) 0.00

3832 Bay Center Place, Hayward, CA 94545

Kosan Biosciences is an established cancer therapeutics company focused on advancing two new classes of anticancer agents through clinical development: heat shock protein 90 (Hsp90) inhibitors and epothilones. Kosan has built an industry-leading position in Hsp90 inhibitors. Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Kosan's drug candidates have demonstrated the potential to overcome resistance after relapse and to synergize the initial activity of existing cancer therapies. Kosan's first and second generation Hsp90 inhibitor clinical programs have demonstrated antitumor activity in multiple indications. Tanespimycin (KOS-953) is a first generation geldanamycin analog prepared in Kosan's proprietary formulation. The agent is currently in Phase I and II clinical trials, primarily for multiple myeloma and HER2-positive breast cancer. In addition, intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin hydrochloride (KOS-1022) are being evaluated in Phase I clinical trials.

Lipid Sciences
(LIPD.PK) 0.01

7068 Koll Center Parkway, Suite 401, Pleasanton, CA 94566-3111

Lipid Sciences is a development-stage biotechnology company that is researching and developing products and processes to treat major medical indications such as cardiovascular disease, HIV and other viral infections in which lipids or fat components play a key role. LIPD's technologies are based on a patented process that selectively and rapidly removes lipids from proteins circulating in blood plasma without disrupting protein function. This process of lipid removal, known as delipidation, potentially reverses the condition while enhancing the body's natural ability to heal itself. The Company believes that its unique delipidation process has the potential for far-reaching implications for human health. It may reverse cardio-and cerebrovascular disease, as well as provide an effective therapy against many infectious agents, including the viruses that cause AIDS, Hepatitis B, Hepatitis C, SARS, Influenza and West Nile.

Maxygen Inc
(MAXY) 5.86

301 Galveston Drive, Redwood City, CA 94063

Maxygen is focused on the development of superior versions of validated major protein pharmaceuticals for the patients who need them. Our lead product candidates address substantial market opportunities in infectious disease, hemostasis and cancer.

Metrika, Inc.
*VENDOR*

510 Oakmead Parkway, Sunnyvale, CA 94085

Metrika Inc. is a manufacturer and marketer of single-use diabetes monitoring products designed to improve the care and quality of life for people with diabetes and other chronic conditions.

Monogram Biosciences
(MGRM) 0.00

345 Oyster Point Blvd., South San Francisco, CA 94080-1913

At Monogram Biosciences, our mission is to improve healthcare by advancing individualized medicine through the discovery and commercialization of innovative products to guide and improve the treatment of HIV, cancer and other serious diseases.

Nektar Therapeutics
(NKTR) 13.63

150 Industrial Road, San Carlos, CA 94070

We are a biopharmaceutical company with a different approach to medicine. We develop drugs that are easier to take, safer to use, longer lasting and more effective. We look closely at existing therapies, and leverage our knowledge and extensive development expertise to evaluate how they can more effectively impact patients’ lives. Our development programs focus on products that fill unmet needs in diabetes, infectious disease, oncology, and eventually other areas, where they can have significant impact

Neurobiological Technologies, Inc.
(NTII.PK) 0.06

2000 Powell Street, Suite 800, Emeryville, CA 94608

Neurobiological Technologies is engaged in the business of acquiring and developing central nervous system (CNS) related drug candidates. The company is focused on therapies for neurological conditions that occur in connection with dementia, Alzheimer's disease, ischemic stroke, neuropathic pain, and brain cancer.

Novacea

601 Gateway Blvd., Suite , South San Francisco, CA 94080

We are a biopharmaceutical company focused on in-licensing, developing and commercializing novel therapies for the treatment of cancer. We currently have two clinical-stage oncology product candidates. Our lead product candidate, Asentar™ (DN-101), is in a Phase 3 clinical trial for the treatment of androgen-independent prostate cancer, or AIPC, also known as hormone-refractory prostate cancer. Our second product candidate, AQ4N, is being investigated in combination with radiation and chemotherapy in a Phase 1/2 clinical trial of patients with newly diagnosed glioblastoma multiforme.

Nuvelo, Inc.
(NUVO) 0.30

201 Industrial Road, Suite 310, San Carlos, CA 94070-6211

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes several acute cardiovascular and oncology programs. The cardiovascular portfolio includes three programs: alfimeprase, a direct acting thrombolytic in development for the treatment of thrombotic- related disorders; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex, which completed a Phase 2 clinical trial in acute coronary syndromes; and preclinical candidate NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical procedures. The oncology portfolio includes two main programs: preclinical candidate NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease; and rNAPc2, which is in Phase 2 development for potential use as a cancer therapy.

ONYX Pharmaceuticals Inc
(ONXX) 25.91

2100 Powell Street, Emeryville, CA 94608

Onyx Pharmaceuticals is developing innovative small molecule cancer treatments based on a molecular understanding of cancer. Our lead product is Nexavar® (sorafenib) tablets, a novel, oral multiple kinase inhibitor that targets proteins involved in both tumor cell proliferation and angiogenesis (the formation of new blood vessels to support cancer cell growth). This product is being developed and marketed in collaboration with Bayer Pharmaceuticals Corporation. Nexavar has been approved by the U.S. and E.U. for the treatment of patients with advanced kidney cancer.

Pain Therapeutics, Inc.
(PTIE) 5.72

416 Browning Way, South San Francisco, CA 94080

We develop novel drugs for pain management and hematology/oncology. We have three investigational drug candidates in clinical programs. Remoxy(tm) and PTI-202 are proprietary, abuse-resistant forms of opioid drugs. Oxytrex(tm) is a novel, next-generation painkiller that potentially offers less physical dependence than currently marketed opioid painkillers. Our early-stage drugs include a novel radio-labeled monoclonal antibody to treat metastatic melanoma, a deadly form of skin cancer. We are also working on a new treatment for patients with hemophilia, a rare blood disorder.

PDL Biopharma, Inc.
(PDLI) 5.77

34801 Campus Drive, Fremont, CA 94555 PDL BioPharma France S.D.S, 118/120 rue de Rivoli, 75001 Paris, France

PDL BioPharma is a leader in the discovery, development, manufacturing and marketing of innovative therapies for serious or life-threatening illnesses, commercially focused on the acute- care, hospital based setting. Our therapeutic emphasis is on the areas of inflammation and autoimmune diseases, cardiovascular disorders and cancer. PDL BioPharma markets several commercial biopharmaceutical products for the hospital setting — Cardene® I.V. for the short-term treatment of hypertension, Retavase® for acute myocardial infarction and IV Busulfex® (Black Box Warning) for conditioning prior to a bone marrow transplant in association with chronic myelogenous leukemia. IV Busulfex is also available outside North America through our distribution partners, a listing of which is available upon request. For important safety information click on the following:Cardene I.V.®, Retavase® and IV Busulfex® . Our leading clinical programs include Nuvion® (visilizumab) , in development for intravenous steroid refractor ulcerative colitis and ularitide in development for acute decompensated heart failure. Two of our other pipeline products in partnership with Biogen Idec-daclizumab for multiple sclerosis and non-respiratory diseases and M200 (volociximab) for cancer. HuLuc63 is currently in development for advanced refractory multiple myeloma.

Peregrine Pharmaceuticals, Inc.
(PPHM) 1.41

14272 Franklin Avenue, Tustin, CA 92780

Peregrine Pharmaceuticals, Inc – targeted therapeutics for cancer and viral diseases: has a portfolio of innovative clinical stage and preclinical product candidates for the treatment of cancer and viral diseases. Bavituximab anti-viral is in Phase I studies for hepatitis C infection and pre-clinical studies in influenza and other life-threatening viral infections and bavituximab anti-cancer is in a Phase I trial for solid tumor cancers. Peregrine’s lead tumor necrosis therapy product, Cotara® is in clinical trials for malignant brain cancer.

Perlegen Sciences, Inc.

2021 Stierlin Court, Mountain View, CA 94043

Perlegen Sciences is working to provide safe and effective medicines to patients worldwide. The company quickly and cost effectively analyzes millions of unique genetic variations in clinical trial participants to develop genetically targeted, late stage therapeutics and diagnostics. Perlegen is actively licensing and developing its own portfolio of medicines as well as collaborating with partners to better position medicines in their portfolios and pipelines.

Pharmacyclics, Inc.
(PCYC) 7.43

995 East Arques Avenue, Sunnyvale, CA 94085

Pharmacyclics is a pharmaceutical company developing innovative treatments for cancer and other diseases. The company is working on a range of clinical and laboratory programs and is pursuing the development of novel drugs aimed at specific disease pathways. The company's most advanced product candidate, Xcytrin® (motexafin gadolinium) is a rationally designed small molecule, the first in a class of drugs that concentrates in cancer cells and disrupts cellular metabolism by a unique mechanism of action. Xcytrin is in late-stage human clinical trials for lung cancer and other oncology indications. The company is developing several other product candidates derived from structure-based research. A series of histone deacetylase (HDAC) inhibitors appear to inhibit tumor growth by interfering with cancer cell DNA transcription. Factor VIIa inhibitors appear to inhibit tumor growth and angiogenesis when complexed with intrinsic tissue factor. Tyrosine kinase inhibitors prevent B-cell maturation and are undergoing investigation for the treatment of lymphomas and autoimmune disorders.

Pherin Pharmaceuticals

123 Saginaw Dr., Redwood City, CA 94063-4717

Pherin Pharmaceuticals, Inc. is focused on the discovery and development of a new family of pharmaceutical compounds called vomeropherins. Vomeropherins non-invasively activate specific chemoreceptors found in nasal passages. The receptors send impulses directly to the hypothalamus and the limbic system – key regulatory control centers of the brain.

Poniard Pharmaceuticals, Inc.
(PARD) 0.48

7000 Shoreline Court Suite 270 South San Francisco, CA 94080 300 Elliott Avenue West, Suite 500, Seattle, WA 98119

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer. We are currently focusing our development efforts on picoplatin, a new generation platinum therapy that provides a differentiated spectrum of activity and an improved safety profile. An intravenous chemotherapeutic agent, picoplatin is designed to overcome platinum resistance associated with the treatment of solid tumors. We are studying picoplatin in clinical trials for the treatment of small cell lung, colorectal and hormone-refractory prostate cancers.

Quark Biotech

6501 Dumbarton Circle, Fremont, CA 94555

Quark Pharmaceuticals is developing new drugs based on our discoveries of novel targets and therapeutic concepts, to treat serious and often life-threatening conditions. Our primary drug candidates belong to the exciting new class of siRNA drugs that work through the recently discovered biological mechanism known as RNA interference.

Questcor Pharmaceuticals Inc
(QSC) 0.00

3260 Whipple Rd., Union City, CA 94587

Questcor is a specialty pharmaceutical company focused on providing prescription drugs for central nervous system (CNS) disorders.

Renovis, Inc.
(RNVS) 0.00

Two Corporate Drive, South San Francisco, CA 94080-7047

Renovis is seeking to discover, develop and commercialize therapeutics for major medical needs in the areas of neurological and inflammatory diseases. Our proprietary preclinical programs are focused on identifying antagonists of selected purinergic receptors as novel potential treatments for a broad spectrum of pain and inflammatory conditions. In addition, we have entered into a collaboration with Pfizer Inc. (Pfizer) to discover and develop product candidates targeting the vanilloid receptor, VR1, for the potential treatment of pain and other diseases and disorders, as well as a collaboration with Genentech, Inc. (Genentech) in the areas of nerve growth and anti-angiogenesis.

Rigel Pharmaceuticals Inc
(RIGL) 8.57

1180 Veterans Boulevard, South San Francisco, CA 94080

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and cancer, as well as viral and metabolic diseases.

Sangamo Biosciences, Inc.
(SGMO) 3.19

Point Richmond Tech Center II, 501 Canal Blvd, Suite A100, Richmond, CA 94804

Sangamo is focused on the research and commercial development of engineered DNA-binding proteins for the regulation of gene expression and for gene modification. The basis of our proprietary technology is the engineering of a naturally occurring class of transcription factors, zinc finger DNA-binding proteins (ZFPs). When linked to functional domains that normally activate or repress gene expression, we create ZFP transcription factors (ZFP TFs) capable of turning genes on or off. ZFPs can also be linked to nuclease domains to create zinc finger nucleases (ZFNs). Engineered ZFNs can modify genomic DNA at a preselected location facilitating either correction or disruption of a specific gene.

SciClone Pharmaceuticals Inc
(SCLN) 2.59

901 Mariner's Island Boulevard, Suite 205, San Mateo, CA 94404

We are building a global portfolio of product candidates to treat cancer and infectious diseases. In the United States and Europe, we are focused on the development of thymalfasin (commercially sold as ZADAXIN®) with ongoing late-stage clinical trials for malignant melanoma and hepatitis C. For the U.S. market, our clinical-stage drug development candidates are SCV-07 for the treatment of viral infectious diseases and RP101 for the treatment of pancreatic cancer.

Scios Inc

1900 Charleston Road, P.O. Box 7210, Mountain View, CA 94039-7210

Scios Inc. is a leader in heart failure treatment and committed to bringing new therapeutics for cardiovascular disease to patients with unmet medical needs. Scios markets a cardiovascular product: NATRECOR® (nesiritide), indicated for acutely decompensated congestive heart failure (ADHF) patients who have dyspnea at rest or with minimal activity.

Stemcells, Inc.
(STEM) 0.80

3155 Porter Drive, Palo Alto, CA 94304-1213

StemCells, Inc. is focused on the discovery and development of stem cell therapeutics that will form the basis of therapies to support or replace cells that have been damaged or lost through disease, injury or genetic defect. Initially, we are focussing on such conditions in the Central Nervous System, Liver and Pancreas. We are a world leader in the discovery and development of human neural stemcell technology using cells derived from adult (i.e. non-embryonic) brain tissue. We use a proprietary process to isolate, purify and expand rare candidate stem cells found in adult human tissue. To date, we have discovered the human neural stem cell as well as a population of rare candidate stem cells found in human liver and pancreas.

Sunesis
(SNSS) 0.38

341 Oyster Point Boulevard, South San Francisco, CA 94080

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other unmet medical needs. We are advancing three proprietary oncology product candidates, SNS-595, SNS-032 and SNS-314, through in-house research and development efforts. All three are inhibitors of the cell division process, known as cell-cycle inhibitors, intended for the treatment of cancer. Sunesis has developed a proprietary method of discovering drugs in pieces, or fragments. We call this fragment-based discovery approach Tethering®. Tethering® is a process whereby a target protein known to be involved in a disease process is engineered to facilitate the binding of small drug fragments. Once a small fragment is identified, the fragment is built out using the target protein’s surface as a template to make a new full-size

SuperGen Inc
(SUPG) 2.06

4140 Dublin Blvd., Suite 200, Dublin, CA 94568

SuperGen is a pharmaceutical company dedicated to the development and commercialization of products intended to treat life-threatening diseases, particularly cancer. The principal activities of the Group are acquisition, development and commercialization of oncology therapies for solid tumors and hematological malignancies.

Telik, Inc.
(TELK) 0.70

3165 Porter Drive, Palo Alto, CA 94304

Telik is dedicated to discovering, developing and commercializing novel small molecule drugs to treat cancer and other serious diseases. Our most advanced development candidate is TELCYTA™ (Canfosfamide), a novel cancer cell-activated chemotherapeutic. A second development candidate, TELINTRA™ (TLK199), is in clinical development in myelodysplastic syndrome, and may also have utility in the treatment of additional blood disorders. These product candidates, and the other candidates in our pipeline, were discovered using our proprietary technology, TRAP™, which enables the rapid and efficient discovery of small molecule drug candidates.

Tercica, Inc.
(TRCA) 0.00

2000 Sierra Point Parkway, Suite 400, Brisbane, CA 94005

Tercica is committed to improving endocrine health. In January 2006, less than four years after Tercica was founded, we commercially launched Increlex™ (mecasermin [rDNA origin] injection), or recombinant human Insulin-like Growth Factor-1 (rhIGF-1), in the United States. Increlex has received orphan drug exclusivity for its approved indication of the long-term treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone.

Theravance, Inc.
(THRX) 14.03

901 Gateway Blvd. South San Francisco, CA 94080

Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and gastrointestinal motility dysfunction. Of our five programs in development, two are in late stage: our telavancin program focusing on treating serious Gram-positive bacterial infections with Astellas Pharma Inc. and our Beyond Advair collaboration with GlaxoSmithKline.

Titan Pharmaceuticals Inc
(TTNP.OB) 0.90

400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080-1921

Titan Pharmaceuticals is focused on the development and commercialization of novel treatments for central nervous system disorders, cardiovascular disease, bone disease and other disorders.

Valentis, Inc.
(URGP.OB) 0.07

533 Airport Blvd., Ste. 400, Burlingame, CA 94010

Valentis, Inc. is a biopharmaceutical company that is applying proprietary synthetic gene delivery, gene regulation and PEGylation technologies to create novel therapeutic products based on genomic discoveries in the fields of cardiovascular disease, oncology, hematology and infectious diseases. Enabled by its expertise in preclinical research and development, clinical development and manufacturing, Valentis has created a broad product portfolio of biopharmaceuticals.

Vanton Research Laboratory, LLC

1870 Arnold Industrial Place, Suite 1000, Concord, CA 94520

Vanton Research Laboratory, LLC is a contract research company dedicated to developing next generation delivery platforms and products for pharmaceutical, nutritional and skin care applications. Founded in 1993, the services include but are not limited to the followings: 1. Custom formulation, 2. Formulation characterization (solids, liquids, semisolids, emulsions, microemulsions, etc.), 3. Formulation development – pharmaceutical, nutraceutical, skincare, and specialty chemical formulations, and 4. Data analysis and consultation. In addition, Vanton is developing a series of in-house products using its proprietary platform technologies, including weight loss capsules, multi-dosage form tablets, controlled release, sustained release, and fast dissolved tablets.

VaxGen, Inc.

349 Oyster Point Boulevard, South San Fransisco, CA 94080

VaxGen is focused on the development, manufacture and commercialization of biologic products for the prevention and treatment of human infectious disease.

Ventria Bioscience

4110 N. Freeway Blvd., Sacramento, CA 95834

In 1997, Ventria's scientists developed a breakthrough protein expression technology with unrivaled efficiency. This proprietary technology platform is called ExpressTec. ExpressTec's cost-efficiency and proven commercial scalability make it possible for Ventria to address unmet and underserved needs in human and animal health by delivering affordable treatments on a global scale.

Vermillion, Inc.
(VRML) 5.68

6611 Dumbarton Circle, Fremont, CA 94555

*Changed name from Ciphergen Biosystems Inc in August 2007*
Vermillion is applying a multi-biomarker approach to identify associations between genes, proteins and diseases that translate into meaningful information about disease states. We plan to use this information to create and commercialize high-value diagnostic tests with sufficient sensitivity and specificity to aid physicians in predicting disease risk, selecting appropriate therapies, monitoring disease progression, and improving outcomes for patients. Our strategy is to create a diagnostics paradigm that is based on risk stratification, multiple-marker testing and information integration. This strategy is based on the belief that any specific disease is heterogeneous; therefore, relying on a single disease marker to provide a simple “yes-no” answer is likely to fail.

VIA Pharmaceuticals, Inc.
(VIAP.PK) 0.11

750 Battery St. Suite 330, San Francisco, CA 94111 101 College Road East, Princeton, NJ 08540

VIA Pharmaceuticals is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA’s lead product candidate, VIA-2291, is in two Phase II clinical studies in patients with acute coronary syndrome and patients with carotid artery disease. VIA’s drug development approach targets inflammation in the blood vessel (vascular) wall, an underlying cause of atherosclerosis and its complications. Atherosclerosis is a common cardiovascular disease that results from chronic inflammation and the build-up of plaque in arterial blood vessel walls. Plaque consists of inflammatory cells, cholesterol and cellular debris. Atherosclerosis, depending on the location of the artery it affects, may result in major adverse cardiovascular events (MACE), such as heart attack and stroke, which are the leading causes of death worldwide.

Vivus
(VVUS) 6.22

1172 Castro Street, Mountain View, CA 94040

VIVUS is focused on research, development and commercialization of products to treat obesity and restore sexual function. VIVUS is developing products for the treatment of obesity, male erectile dysfunction, female sexual dysfunction, and menopause,

Xoma LLC
(XOMAD) 3.21

2910 Seventh Street, Berkeley, CA 94710

XOMA is a leader in the discovery, development and manufacture of therapeutic antibodies. XOMA’s exceptionally broad technology platform, leading scientific expertise, and fully integrated product development infrastructure, extends from antibody discovery to regulatory approval. A proven development partner and technology licensor, XOMA receives royalties from Genentech for RAPTIVA® (efalizumab) and LUCENTIS® (ranibizumab injection). Our pipeline includes an expanding number of proprietary products and collaborative programs at various stages of clinical and preclinical development.

Zyomyx

26101 Research Road, Hayward, CA 94545

With 8+ years of product development experience in protein biochips and biointerface technologies, Zyomyx develops and commercializes proprietary protein analysis platforms, including protein profiling bioassays.